Rodman & Renshaw Fireside Chat | November 2026 - AGENUS INC

Financial Performance:

• Company executed a private placement (PIPE) closed July 13, securing $85 million upfront with an additional $255 million in potential proceeds via Series A and Series B warrants.
• Warrants are exercisable at $4.02 (Series A) and $5.03 (Series B) per share; full exercise would generate $255 million, extending cash runway to Q1 2029.
• Valuation metrics referenced a transaction price premium of $3.35 above market rates at closing.
• Addressable market for MSS colon cancer estimated at over $7 billion in the U.S., assuming a therapy cost of ~$200,000 per course.

Guidance and Future Outlook:

• Anticipates first patient enrollment (FPE) in the Phase 3 "Robin" trial in Q1 2025.
• Interim pathologic response rate data for the first 100 patients expected in Q4 2026, triggering Series B warrant expiration.
• Primary endpoint (Event-Free Survival) interim analysis projected for H2 2028; full readout targeted for H2 2030.
• Goal is to establish a new standard of care for MSS colorectal cancer, potentially allowing chemotherapy de-escalation or omission in patients achieving pathologic complete response (pCR).

Business Segments and Product Lines:

• Boloncelumab (Bot-Bal): An engineered anti-CTLA-4 antibody with FC-enhancement mutations designed to bind FcγRIIIa, converting "cold" MSS tumors into "hot" tumors by recruiting CD4+/CD8+ T-cells and eliminating regulatory T-cells (Tregs).
• Neoadjuvant Focus: Pivot to early-stage MSS colon cancer based on superior activity in NEST and UNICORN studies showing high pCR and major pathologic response (MPR) rates (30% pCR in MSS).
• Oncology Portfolio: Strong data in metastatic CRC (21% response rate, median OS 17 months) and ovarian cancer (50% 2-year survival plateau); French regulatory access granted for metastatic CRC, ovarian cancer, and sarcoma.
• Pipeline Expansion: Ongoing Investigator-Sponsored Trials (ISTs) in neoadjuvant MSS rectal cancer and the multinational NeoASIS study (sarcoma, triple-negative breast cancer, Merkel cell carcinoma).

Market and Competitive Landscape:

• MSS colorectal cancer (85% of the population) represents a significant unmet need with no treatment advances in 20+ years since oxaliplatin (2004).
• Market validation: The company's success has spurred a "renaissance" in CTLA-4 assets, with multiple fast-follower competitors now entering the clinic with activated FC or masked CTLA-4 antibodies.
• Company maintains a substantial clinical lead and robust data set compared to early-stage competitors.
• Target market includes high-risk Stage II and Stage III patients, where current standard of care involves surgery followed by adjuvant chemotherapy with significant neurotoxicity (oxaliplatin).

Risks and Challenges:

• Trial Execution: Dependence on the success of the Robin Phase 3 trial (850 patients) to demonstrate Event-Free Survival benefit (target Hazard Ratio 0.65).
• Safety: Must maintain a tolerable safety profile in the neoadjuvant setting (intact immune system) which differs from the metastatic setting; requires careful dose management to avoid overtreatment.
• Chemo De-escalation: Risk that the standard-of-care control arm (surgery + chemo) performs better than expected, potentially masking the efficacy of Bot-Bal if patients in the control arm receive higher cumulative chemo exposure.
• Competition: Increasing activity from fast-followers in the CTLA-4 space could dilute market advantage if the company fails to secure broad label approval quickly.

Management Commentary and Tone:

• Tone was highly confident and enthusiastic, characterizing the data as "compelling" and "momentous."
• Management emphasized the "de-risked" nature of the asset due to consistent translational data and robust clinical activity in cold tumors.
• CCO Robin Taylor expressed strong conviction in the mechanism of action, noting the unique ability to ignite immune responses in tumors previously deemed unresponsive to immunotherapy.
• CFO highlighted a clear value creation pathway, aligning financing milestones with clinical readouts to reassure investors.

Analyst Questions and Answers:

• Question: Does the inclusion of standard chemo in the control arm harm efficacy readouts? Answer: No, as the control arm performance is well-established; Bot-Bal aims to show superior recurrence rates with less chemo, improving Quality of Life (QoL).
• Question: Why switch to neoadjuvant for Phase 3? Answer: To leverage an intact tumor environment for better immune education and to address the high-risk population where no new therapies have existed in decades.
• Question: Is there data on MSI-High tumors? Answer: Yes, UNICORN showed 100% Major Path Response in MSI-High with Bot-Bal + PD-1; expansion into this area is a future consideration.
• Question: Are there plans for China enrollment? Answer: Yes, China is a key market due to high patient volume, though regulatory approvals for specific sites are pending.
• Question: How is safety managed in early-stage patients? Answer: Dosing is reduced (1 dose of Bot-Bal vs. 2-4 in metastatic) and the immune system is healthier, resulting in significantly lower toxicity than in late-line settings.

Other Key Points:

• Mechanism of Action: The FC-enhancement allows tighter synapse formation with antigen-presenting cells, expanding the recognition of weak neoantigens and turning cold tumors "hot."
• Translational Success: Biopsies confirm the elimination of Tregs and infiltration of CD4+/CD8+ T-cells in treated patients.
• Strategic Alignment: The financing structure ties capital infusion directly to clinical milestones (60 patients enrolled for Series A; interim response data for Series B), creating a self-funding model for execution.
• Global Scope: The Robin trial is designed as a global study, opening in US, South America, Australia, Europe, and Asia, with high-volume site selection protocols.